Jpmorgan Chase & CO Evolus, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Evolus, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 169,926 shares of EOLS stock, worth $1.85 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
169,926
Previous 213,954
20.58%
Holding current value
$1.85 Million
Previous $2.32 Million
18.57%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding EOLS
# of Institutions
168Shares Held
47.8MCall Options Held
130KPut Options Held
51K-
Perceptive Advisors LLC New York, NY5.36MShares$58.3 Million2.27% of portfolio
-
Tang Capital Management LLC San Diego, CA4.85MShares$52.8 Million6.69% of portfolio
-
Black Rock Inc. New York, NY4.01MShares$43.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.2MShares$34.8 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.82MShares$30.8 Million2.72% of portfolio
About Evolus, Inc.
- Ticker EOLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 56,094,800
- Market Cap $611M
- Description
- Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...